1,3-Diallyl-8-cyclohexylxanthine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1,3-Diallyl-8-cyclohexylxanthine
• 英文别名: 8-cyclohexyl-1,3-bis(prop-2-enyl)-7H-purine-2,6-dione
• 化学式: C₁₇H₂₂N₄O₂
• 分子量: 314.4
• InChiKey: JPIQZRAYPNKFEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  69.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Method for treating cystic fibrosis
  申请人：The Government of the USA, Dept of Health and Human Services, The National Institutes of Health

  公开号：US20030114375A1

  公开（公告）日：2003-06-19

  The present invention provides a method of identifying CFTR-binding compounds for treating cells having a reduced apical Cl − conductance, such as cystic fibrosis cells. This identification method involves the use of polypeptide I&agr;, which constitutes a portion of the CFTR protein. The present invention also provides a method of treating CF cells by contacting cells having a reduced apical Cl − conductance with a therapeutically effective quantity of a compound selected by the present inventive identification method. Preferred compounds for such treatment have little or no affinity for adenosine cell receptors. The present invention provides novel compounds useful in practicing the present inventive method, as well as pharmaceutical compositions containing such compounds.

  本发明提供了一种鉴定 CFTR 结合型化合物的方法，用于治疗顶端 Cl - 传导性降低的细胞，如囊性纤维化细胞。这种鉴定方法涉及使用多肽 I&agr;，它构成 CFTR 蛋白的一部分。本发明还提供了一种治疗 CF 细胞的方法，该方法通过接触具有降低的顶端 Cl - 传导性降低的细胞接触本发明鉴定方法所选择的治疗有效量的化合物。用于此类治疗的优选化合物对腺苷细胞受体的亲和力很小或没有亲和力。本发明提供了可用于实施本发明方法的新型化合物以及含有此类化合物的药物组合物。
• Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
  申请人：Pollard Bette

  公开号：US20060234955A1

  公开（公告）日：2006-10-19

  A method of inhibiting the secretion of IL-8 and other pro-inflammatory cytokines from cells secreting elevated levels of these compounds is provided. The method includes contacting the cell with a composition comprising a cardiac glycoside such as oleandrin. The cardiac glycoside can be used to treat cystic fibrosis and other IL-8 dependent disorders by lowering levels of spontaneously secreted IL-8 and other pro-inflammatory cytokines. Oleandrin was found to suppress the secretion of IL-8 from cultured CF lung epithelial cells in the nanomolar concentration range. Structure-activity relationships (SARs) for cardiac glycosides are also elucidated.

  本发明提供了一种抑制分泌高水平 IL-8 和其他促炎细胞因子的细胞分泌这些化合物的方法。该方法包括使细胞与含有强心苷（如齐墩果苷）的组合物接触。通过降低自发分泌的 IL-8 和其他促炎细胞因子的水平，强心苷可用于治疗囊性纤维化和其他 IL-8 依赖性疾病。研究发现，在纳摩尔浓度范围内，齐墩果素可抑制培养的囊性纤维化肺上皮细胞分泌 IL-8。此外，还阐明了强心苷的结构-活性关系（SARs）。
• A METHOD OF IDENTIFYING CFTR-BINDING COMPOUNDS USEFUL FOR ACTIVATING CHLORIDE CONDUCTANCE IN ANIMAL CELLS
  申请人：THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services

  公开号：EP0794963A2

  公开（公告）日：1997-09-17
• XANTHINE DERIVATIVES COMPOUNDS USEFUL FOR ACTIVATING CHLORIDE CONDUCTANCE IN ANIMAL CELLS
  申请人：THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services

  公开号：EP0794963B1

  公开（公告）日：2005-06-01
• PHARMACEUTICAL FORMULATIONS COMPRISING SUBSTITUTED XANTHINE COMPOUNDS
  申请人：Sciclone Pharmaceuticals, Inc.

  公开号：EP1448203A1

  公开（公告）日：2004-08-25